📰 Genentech News

Page 19 - Genentech News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Genentech. Real-time updates on events, politics, business and more.

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

April 7, 2024

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patien

Cooper City United States University Of Central Florida New Zealand New York Elanaj Fertig

Source: newswise.com

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer -April 07, 2024 at 02:00 pm EDT

April 7, 2024

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran continue to show polyspecific T cell responses up to three...

San Diego United States Vinod Balachandran Fosun Pharma Memorial Sloan Kettering Cancer Center Roche Group

Source: marketscreener.com

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer -April 07, 2024 at 02:00 pm EDT

April 7, 2024

United States San Diego Fosun Pharma Vinod Balachandran Globenewswire Inc American Association For Cancer Research

Source: marketscreener.com

Three-year Phase 1 Follow-Up Data for mRNA-based

April 7, 2024

Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122,...

United States San Diego Vinod Balachandran Fosun Pharma American Association For Cancer Research Roche Group

Source: globenewswire.com

Investegate | Company Announcement

April 7, 2024

Investegate announcements from Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

United States San Diego Fosun Pharma Vinod Balachandran Roche Group Memorial Sloan Kettering Cancer Center

Source: investegate.co.uk

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Personalized Vaccine for Liver Cancer Shows Promise in Clinical Trial

April 7, 2024

Adding a personalized anti-tumor vaccine to standard immunotherapy is safe and about twice as likely to shrink cancer as standard immunotherapy alone for patien

United States Cooper City New Zealand New York University Of Central Florida Elanaj Fertig

Source: newswise.com

Addressing the Challenges of Implementing Bispecific Antibodies in Health Care Centers

April 6, 2024

There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.

United States Melissa Royero Hematology Oncology Pharmacy Association American Society Of Hematology Annual Meeting Janssen Biotech Inc American Society Of Clinical Oncology Annual Meeting

Source: pharmacytimes.com

Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

April 5, 2024

LEXINGTON, Mass., April 5, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on April...

Curis Inc Drug Administration Prnewswire Curis Inc Company Fourth Roche Group Compensation Committee

Source: marketscreener.com

Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer

April 5, 2024

AUSTIN, Texas, April 05, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress 2024 in Paris, France. The analysis evaluates outcomes in muscle-invasive bladder cancer (MIBC) patients who tested serially negative with Signatera™, Natera’s personalized and tumor-informed molecular residual disease (MRD) test.

United States France General San Carlos John Simmons Drug Administration Clinical Laboratory Improvement Amendments

Source: yahoo.com